Clinical Trial Update: A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating Fruquintinib combined with RC48 for previously treated HER2-positive locally advanced or metastatic gastric or gastroesopha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• RC48 (disitamab vedotin)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN